Loading…
Acumen Pharmaceuticals, Inc. is projected to rise to $2.29 by 2027, a +6% move from its current price of $2.15. ABOS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $2.07 | $2.15 | $2.23 | +0.02% |
| Aug 5 | $2.04 | $2.15 | $2.27 | +0.05% |
| Aug 6 | $2.02 | $2.15 | $2.29 | +0.07% |
| Aug 7 | $2.00 | $2.15 | $2.32 | +0.09% |
| Aug 8 | $1.98 | $2.15 | $2.34 | +0.12% |
| Aug 9 | $1.97 | $2.15 | $2.36 | +0.14% |
| Aug 10 | $1.95 | $2.15 | $2.38 | +0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.95 | $2.15 | $2.38 | +0.16% |
| Week 2 | $1.88 | $2.16 | $2.48 | +0.33% |
| Week 3 | $1.82 | $2.16 | $2.56 | +0.49% |
| Week 4 | $1.78 | $2.16 | $2.63 | +0.65% |
| Week 5 | $1.74 | $2.17 | $2.70 | +0.82% |
| Week 6 | $1.71 | $2.17 | $2.76 | +0.98% |
| Week 7 | $1.68 | $2.17 | $2.82 | +1.15% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Acumen Pharmaceuticals, Inc. is a healthcare company described as a clinical-stage biopharmaceutical company that develops targeted therapies for the treatment of Alzheimer's disease.
It focuses on advancing sabirnetug (ACU193), a targeted immunotherapy drug candidate, which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
The company has collaboration and license agreements with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease.
The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
ABOS is a healthcare stock currently priced at $2.22 with a market capitalization of $160.35M, ranking 3980 by market cap.
The near-term technical backdrop includes RSI14 of 40, a SMA50 of $2.44 and a SMA200 of $2.33, with a support level at $2.15 and a resistance at $2.77. The 30-day range spans from $1.64 to $3.00.
The year-by-year forecast shows a flat-to-moderate path through 2029, followed by a bullish long-run trajectory. The 2030 avg is $2.84 with ROI 28, and the 2050 avg is $9.59 with ROI 331.9. Max forecasts reach $22.05 by 2050, reflecting meaningful upside potential over the longer term.
A major floor 21.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.9% away) — a key level to hold.
The nearest ceiling, 28.8% above — a clean break opens room to run.
A major ceiling 39.7% above — clearing it would confirm fresh momentum.
Key ABOS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABOS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.18 | Sell | $2.17 | Sell |
| MA 10 | $2.19 | Sell | $2.21 | Sell |
| MA 20 | $2.35 | Sell | $2.28 | Sell |
| MA 50 | $2.38 | Sell | $2.37 | Sell |
| MA 100 | $2.51 | Sell | $2.40 | Sell |
| MA 200 | $2.35 | Sell | $2.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.06 | Neutral |
| Stoch RSI (14) | 31.21 | Neutral |
| CCI (20) | -65.17 | Neutral |
| Williams %R (14) | -90.48 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -3.15 | Sell |
| Bollinger %B (20,2) | 0.27 | Neutral |
| Stochastic %K (14) | 9.52 | Buy |
| TRIX (15) | -0.35 | Sell |
| Awesome (5,34) | -0.20 | Sell |
| Ultimate (7,14,28) | 39.45 | Neutral |
| Momentum (10) | -0.10 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 2.16 | Sell |
| ADX (14) | 15.40 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is Neutral overall. RSI(14) is 40, with SMA50 at $2.44 and SMA200 at $2.33, suggesting prices near a pivotal zone around the 50-day and 200-day averages.
Key near-term support sits at $2.15 and resistance at $2.77, with a 30-day price range of $1.64 to $3.00. This setup implies limited near-term upside unless prices break above $2.77 or below $2.15.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.72 | $2.15 | $2.80 | 0% | Neutral | |
| $1.77 | $2.29 | $3.17 | +6% | Neutral | |
| $1.69 | $2.28 | $3.31 | +6% | Neutral | |
| $1.53 | $2.13 | $3.22 | -1% | Neutral | |
| $2.00 | $2.88 | $4.48 | +34% | Bullish | |
| $2.30 | $3.39 | $5.42 | +58% | Bullish | |
| $2.18 | $3.30 | $5.41 | +53% | Bullish | |
| $2.38 | $3.69 | $6.18 | +72% | Bullish | |
| $2.24 | $3.55 | $6.06 | +65% | Bullish | |
| $2.12 | $3.43 | $5.98 | +60% | Bullish | |
| $2.85 | $5.13 | $9.63 | +139% | Bullish | |
| $4.59 | $9.97 | $20.88 | +364% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.72 | $2.15 | $2.50 | +0.00% |
| September 2026 | $1.75 | $2.10 | $2.59 | -2.55% |
| October 2026 | $1.82 | $2.20 | $2.75 | +4.81% |
| November 2026 | $1.80 | $2.19 | $2.78 | -0.33% |
| December 2026 | $1.78 | $2.18 | $2.80 | -0.24% |
Click any year to see its month-by-month ABOS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ABOS to range from $1.72 to $2.80 through 2026. The $2.15 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The ABOS price prediction for 2027 points to an average of $2.29 (low $1.77, high $3.17) — a potential gain of +6% on today's $2.15. A consolidation phase looks the most probable path here.
In 2028, ABOS is projected to trade between $1.69 and $3.31, averaging $2.28 — a potential gain of +6% from today's $2.15. That is 0% versus the projected 2027 average. Price action looks broadly range-bound.
Acumen Pharmaceuticals, Inc.'s 2029 outlook centres on $2.13, within a $1.53 to $3.22 range. That is -6% versus the projected 2028 average. That marks a -1% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, ABOS could reach as high as $4.48, with a base case around $2.88 and support toward $2.00 — roughly +34% from $2.15. Momentum favours further upside here.
Expect ABOS to range from $2.30 to $5.42 through 2031. The $3.39 average target implies a +58% move from current prices. That is up +18% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The ABOS price prediction for 2032 points to an average of $3.30 (low $2.18, high $5.41) — a potential gain of +53% on today's $2.15. Momentum favours further upside here.
In 2033, ABOS is projected to trade between $2.38 and $6.18, averaging $3.69 — a potential gain of +72% from today's $2.15. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Acumen Pharmaceuticals, Inc.'s 2034 outlook centres on $3.55, within a $2.24 to $6.06 range. That is -4% versus the projected 2033 average. That marks a +65% change versus current levels. Momentum favours further upside here.
By 2035, ABOS could reach as high as $5.98, with a base case around $3.43 and support toward $2.12 — roughly +60% from $2.15. Buyers look set to stay in control over this stretch.
Expect ABOS to range from $2.85 to $9.63 through 2040. The $5.13 average target implies a +139% move from current prices. That is up +49% on the projected 2035 average. Momentum favours further upside here.
The ABOS price prediction for 2050 points to an average of $9.97 (low $4.59, high $20.88) — a potential gain of +364% on today's $2.15. Buyers look set to stay in control over this stretch.
Investing $1,000 in ABOS today (≈ 465.116279 ABOS) could be worth
$4,636.26
+$3,636.26 (+364%) by 2050 · US Dollar
Based on the average projected ABOS price of $9.97 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABOSwould be worth at today's price.
$1,000 invested in ABOS on Jul 31, 2025 (≈ 714.285726 ABOS) would be worth
$1,535.71
+$535.71 (+53.6%) today · 1.54× · US Dollar
Based on a ABOS entry price of $1.4 vs. today's $2.15.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.13 | $1,009.39 | +0.9% |
| 1 month ago | $2.59 | $830.12 | -17.0% |
| 3 months ago | $2.38 | $903.36 | -9.7% |
| 6 months ago | $2.59 | $830.12 | -17.0% |
| 1 year ago | $1.4 | $1,535.71 | +53.6% |
| All time (5.0y) ago | $14.65 | $146.76 | -85.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABOS forecast.
Our base-case forecast reaches $4.30 around 2040.
Implied market cap at $4.30: $310.58M
The multi-year forecast points to a bullish trajectory beginning around 2030, with an avg price of $2.84 and an ROI of 28, rising to $3.29 (ROI 48.3) in 2031 and $3.27 (ROI 47.2) in 2032, then $3.66 (ROI 65) in 2033 and $3.32 (ROI 49.7) in 2034. By 2035, the avg is $3.20 (ROI 44.2).
The forecast accelerates further in the 2040s, with 2040 avg $4.61 (ROI 107.8) and a 2050 avg of $9.59 (ROI 331.9). The 2050 max is $22.05, and the 2050 sentiment is Bullish. These figures imply substantial long-term upside while recognizing volatility and uncertainty along the way.
Tap a question to reveal the answer.
2030 min $1.86, avg $2.84, max $4.69; ROI 28; sentiment Bullish.
Long-term forecasts show Bullish sentiment with 2030–2050 upside (e.g., 2050 avg $9.59 and max $22.05), but there is near-term volatility and years with negative ROI (e.g., 2028 ROI -2.5 and 2029 ROI -6).
Yes; the 2050 max is $22.05, and the 2040 max is $9.43, so surpassing $10 becomes possible by 2050 based on the provided forecasts.
Near-term declines occur in 2028 and 2029 (min/max and ROI shown in the forecast), and the longer horizon includes volatility with a high annualized volatility percentage implied by the forecast ranges.
Current price is $2.22 and market cap is $160.35M.
Acumen Pharmaceuticals, Inc. Community Discussion
0Share your Acumen Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.